SynthesisBMC pulmonary medicine2022
Comparison of the clinical manifestations and chest CT findings of pulmonary cryptococcosis in immunocompetent and immunocompromised patients: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 18 citations in OpenAlex.
- Rapid, Recurrent Unilateral Pleural Effusion Presenting as Cryptococcus Infection in a Non-immunocompromised Host.Cureus · 2026Article
- Based on a radiomics-clinical nomogram to predict the therapeutic effect of pulmonary cryptococcosis pneumonia.Scientific reports · 2026Article
- Severe Pulmonary Cryptococcosis in an Immunocompetent Patient Presenting With Acute Respiratory Failure.Cureus · 2026Article
- Solitary Cavitary Right Upper Lobe Lesion Revealing Disseminated Cryptococcosis in a Kidney Transplant Recipient: A Diagnostic Challenge.Case reports in pulmonology · 2026Article
- Pulmonary cryptococcosis with or without immunocompromise: a retrospective comparative study of clinical and CT features and influential factors for lesion absorption.Frontiers in medicine · 2026Article
- Recurrent Pulmonary Nodules, from Pulmonary Cryptococcosis to ANCAAssociated Vasculitis: A Case ReportCurrent medical imaging · 2026Article
- Pulmonary sarcoidosis complicated with pulmonary cryptococcosis: a case report.Frontiers in medicine · 2026Article
- Pulmonary mycoses: a clinical perspective.Breathe (Sheffield, England) · 2026Review
- Intranodular and perinodular radiomics features based on non-contrast CT to distinguish pulmonary cryptococcosis from lung adenocarcinoma: a two-center study.Frontiers in oncology · 2026Article
- Invasive pulmonary cryptococcosis mimicking metastatic lung cancer: A case report and review of literature.World journal of clinical cases · 2025Article
- Clinical-imaging diversity of exudative pulmonary cryptococcosis with different immune states.Scientific reports · 2025Article
- Cryptococcosis in Pediatric Renal Transplant Recipients: Comparative Insights from Adult Cases.Medicina (Kaunas, Lithuania) · 2025Review
- Is Pulmonary Mycoses Shadowed by Tuberculosis? Mandate to Hit the Bull's Eye-An Indian Perspective.Pathogens (Basel, Switzerland) · 2025Review
- Evaluation of Inborn Errors of Immunity Among Patients with Opportunistic Pulmonary Infection.Clinics in chest medicine · 2025Review
- Metagenomic next-generation sequencing facilitates precision treatment and prognostic improvement in pulmonary cryptococcosis.Frontiers in cellular and infection microbiology · 2025Article
- Clinical imaging diagnosis of pulmonary cryptococcosis with different therapeutic responses.Scientific reports · 2024Article
- Diffuse Alveolar Hemorrhage Caused by Disseminated Cryptococcosis in a Patient With Systemic Lupus Erythematosus.Cureus · 2024Article
- The Differential Diagnostic Value of Chest Computed Tomography for the Identification of Pathogens Causing Pulmonary Infections in Patients with Hematological Malignancies.Infection and drug resistance · 2024Article
- Metagenomic next-generation sequencing contributes to the diagnosis of mixed pulmonary infection: a case report.Annals of clinical microbiology and antimicrobials · 2022Article
- Extensive Pulmonary Cryptococcosis as a Presentation in an Immunocompetent Young Male: A Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Finding.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveThe purpose of our study was to perform a meta-analysis and systematic review to compare differences in clinical manifestations and chest computed tomography (CT) findings between immunocompetent and immunocompromised pulmonary cryptococcosis (PC) patients.
methodsAn extensive search for relevant studies was performed using the PubMed, EMBASE, Cochrane Library, and Web of Sciences databases from inception to September 30, 2021. We included studies that compared the clinical manifestations and chest CT findings between immunocompetent and immunocompromised PC patients. Study bias and quality assessment were performed using the Newcastle-Ottawa Scale (NOS).
resultsNine studies involving 248 immunocompromised and 276 immunocompetent PC patients were included in our analysis. The NOS score of each eligible study was above 5, indicating moderate bias. The proportion of elderly patients (> = 60 years old) in the immunosuppressed group was significantly higher than that in the immunocompetent group (OR = 2.90, 95% CI (1.31-6.43), Z = 2.63, p = 0.01). Fever (OR = 7.10, 95% CI (3.84-13.12), Z = 6.25, p < 0.000) and headache (OR = 6.92, 95% CI (2.95-16.26), Z = 4.44, p < 0.000) were more common in immunosuppressed patients. According to thin-section CT findings, lesions were more frequently distributed in the upper lobe (OR = 1.90, 95% CI (1.07-3.37), Z = 2.2, p = 0.028) in immunocompromised individuals. The proportions of patients with cavity sign (OR = 5.11, 95% CI (2.96-8.83), Z = 5.86, p = 0.00), ground-glass attenuation (OR = 5.27, 95% CI (1.60-17.35), Z = 2.73, p = 0.01), and mediastinal lymph node enlargement (OR = 2.41, 95% CI (1.12-5.20), Z = 2.24, p = 0.03) were significantly higher in immunocompromised patients.
conclusionNo significant differences in nonspecific respiratory symptoms were found between immunocompromised and immunocompetent PC patients. Nevertheless, fever and headache were more common in immunocompromised patients. Among the CT findings, cavity, ground-glass attenuation, and mediastinal lymph node enlargement were more common in immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.